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A B S T R A C T
Endometrial cancer is the most common gynecological malignancy in Croatia. The aim of this study was to determine
the immunohistochemical expression of estrogen receptors (ER) and progesterone receptors (PGR) in cancer cells and in
the myometrium and to correlate it with prognostic factors of endometrial carcinoma. ER positivity in carcinoma cell nu-
clei was found in 42 cases (73.7%) and PGR positivity was found in 39 cases (68.4%). Loss of ER in carcinoma cell nuclei
correlated with larger tumor size (p=0.041), poor carcinoma differentiation (p=0.012), a more aggressive histological
type (p<0.001), lymphovascular space invasion (p=0.002) and a higher surgical stage (p=0.037). Loss of PGR in carci-
noma cell nuclei correlated with an increased age in patients (p=0.009), poor tumor differentiation (p=0.002), a more
aggressive histological type (p<0.001), lymphovascular space invasion (p=0.002) and a higher surgical stage (p<0.001).
The lower expression of both receptors did not correlate with the depth of myometrial invasion. Regarding the status of
receptors in the myometrium, loss of PGR in the myometrium correlated with a more aggressive histological type (p=
0.005) and a lack of ER in the myometrium tended to correlate with tumor growth (p=0.059). In conclusion, the loss of
both hormone receptors in carcinoma cells and loss of PGR in the myometrium was a predictor of a more aggressive type
of endometrial cancer and a poor prognosis.
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Introduction
Endometrial cancer (EC) is the most common gyne-
cological malignancy in the Western world responsible for
1–2% of all deaths from cancer in women1,2. According to
the Croatian National Institute of Public Health, the inci-
dence of EC in 2009 was 25.3/100,000 which is 6.0% of all
new malignancies diagnosed in women every year. The
majority of endometrial malignances occur in postmeno-
pausal women. According to the World Health Organiza-
tion, EC has several histological types. The most common
is endometrioid adenocarcinoma (75%). Papillary serous
(5–10%) and clear cell (1–5%) carcinomas are less common
types1,2. Type I endometrioid adenocarcinomas are estro-
gen dependent, low grade and often diagnosed in early
stage with a favorable prognosis. The five-year survival
rate is over 80.0%. Type II cancers usually have papillary
serous or clear cell histology. They are estrogen non-de-
pendent, high grade, and often with a more aggressive
clinical course. Studies regarding EC have shown the
presence of multiple prognostic factors: surgical stage, pa-
tient age, histological type, tumor grade, depth of myo-
metrial invasion, cervical invasion, lymphovascular space
invasion (LVSI), lymph node involvement, tumor size, ex-
pression of estrogen receptors (ER) and expression of pro-
gesterone receptors (PGR)3–5. The endometrium and myo-
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metrium are highly hormone-regulated tissues with the
expression of both, estrogen and progesterone receptors.
The majority of endometrial cancers are ER and PGR pos-
itive (35–90%)6–8. Loss of ER correlates with a higher tu-
mor grade, higher clinical stage, deeper myometrial inva-
sion, LVSI and poor overall survival9. On the other hand,
loss of PGR correlates with a younger age of patients,
higher tumor grade, higher clinical stage, LVSI and deeper
myometrial invasion10,11. Loss of PGR also correlates with
a relapse of the disease and contributes to tumor progres-
sion but does not correlate with overall survival9,10,12. On
the contrary, according to Bender, loss of PGR is a predic-
tor of a poor clinical outcome12,13. The evaluation of ex-
pression levels of ER and PGR in endometrial cancer is a
very common procedure in modern practice. However, the
significance of such tests remains controversial11. There-
fore, the aims of this study were to analyze ER and PGR
expression in cancer cells and in the surrounding myo-
metrium, and to present the correlation of their expres-
sion with other EC prognostic factors.
Patients and Methods
In this study we used paraffin embedded endometrial
cancer samples taken from 57 patients surgically treated
and diagnosed between 2007 and 2010 at the Depart-
ment of Pathology, University Hospital for Tumors, Za-
greb, Croatia. Data were retrospectively collected from a
clinical data base. The patient’s age, tumor size (mm),
tumor histological grade (I, II, III), depth of myometrial
invasion (less or more than 50% of myometrium thick-
ness), LVSI (present or absent) and FIGO surgical stage
were collected from pathology reports. For statistical
analysis, the FIGO classification was grouped in clinical
stage I (disease limited to uterus) and clinical stage II
(disease extended beyond uterus). The endometrioid his-
tological type of EC was grouped as low risk (Type 1)
while clear cell and papillary serous histological types
were grouped as high risk cancers (Type 2).
Immunohistochemical analysis
An immunohistochemical reaction was carried out for
the detection of steroid hormone receptors expression in
cancer and myometrial cells. Sections of 2–3 mm were cut
from FFPE blocks and mounted on silanized slides and
dried for one hour at 60 °C. The sections were dewaxed in
xylene and rehydrated in a series of graded alcohols. An-
tigen retrieval was performed in pH 9.0 Tris/EDTA buf-
fer in Dako PT link at 97 °C for 20 minutes. Prior to
immunohistochemical staining endogenous peroxidase
activity was blocked using 3.0% hydrogen peroxide for
five minutes. The primary monoclonal antibodies against
estrogen receptor á (ER, clone 1D5, Dako Denmark, di-
luted 1:40) and progesterone receptor A (PGR, clone PgR
636, Dako Denmark, diluted 1:75) were applied for 30
minutes. Visualization was performed using a universal
secondary antibody for 30 minutes (EnVision Flex,
K8010, Dako Denmark). Counterstaining was performed
using hematoxylin for one minute. The slides were dehy-
drated, cleared with xylene and covered.
We evaluated the expression of steroid receptors in
EC cells and in surrounding myometrium cells on the
same slide. Positive immunohistochemical staining has
nuclear reaction. We counted 1,000 cells and scored the
percentage of immunopositive nuclei, using high-power
magnification (×40 objective and ×10 ocular).
Statistical analysis
Differences in the expression of estrogen and proges-
terone receptors (as a percentage) between binary vari-
ables – disease risk type (low or high risk), myometrial
invasion (less or more than 50% of depth), LVSI (present
or absent) and surgical stage (disease limited to the
uterus or extended beyond the uterus) were tested with a
Student T-test for independent samples. Correlations be-
tween hormone receptor expressions, both in the tumor
and myometrium, age, tumor size, histological grade and
surgical stage were tested using a nonparametric Spear-
man correlation analysis. All analyses were performed
using StatSoft software Statistica 7.0 (Tulsa, USA). We
set the definition of statistical significance to 0.05.
Results
The detailed pathohistological data of 57 patients
with EC are presented in Table 1. Endometrial carci-
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EC – endometrial cancer, ER – estrogen receptors, PGR – pro-
gesterone receptors, LVSI – lymphovascular space invasion,
FIGO – International Federation of Gynecology and Obstetrics
noma prevails in older women; the median age was 66
years. Patients with a higher risk type of endometrial
cancer were older (median age 70 years) than patients
with a lower risk type (median age 65 years). High-risk
carcinomas had 55.5% grade III carcinomas compared to
25.6% grade III in low risk carcinomas. Half had myo-
metrial invasion in more than 50% of the myometrium
thickness while low-risk carcinomas had an invasion of
over 50.0% in 38.5% of cases. Lymphovascular space in-
vasion was also associated with higher risk type, with
77.8% positivity. Larger tumor size and a higher histolo-
gical grade showed the impact on the depth of myoin-
vasion (R=0.338, p=0.011 and R=0.437, p<0.001, retro-
spectively). In addition, larger tumor size and a higher
histological grade have an impact on LVSI (R=0.333,
p=0.012 and R=0.676, p<0.001).
The immunohistochemical expression of ER was found
in 42 cases (73.7%) and PGR was found in 39 cases
(68.4%) of cancer nuclei. In addition, hormone receptors
were predominantly positive in the myometrium of the
uteri (Figures 1 and 2). Negative receptors in the myo-
metrium were found in four cases (7.0%) for ER and six
cases (10.5%) for PGR (Table 1) (Figure 3).
Correlations between hormone receptors in tumor
cells and the myometrium and EC prognostic factors are
presented in Tables 2 and 3. In our results (Table 2), the
expression of PGR in cancer inversely correlated with
the age of patients (p=0.009). Both receptors, ER and
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Fig. 1. Nuclear immunohistochemical expression of estrogen re-
ceptors; positive expression in carcinoma cells and strong expres-
sion in myometrial cells (x50).
Fig. 2. Nuclear immunohistochemical expression of progesterone
receptors; negative expression in carcinoma cells and moderate
positive expression in myometrial cells (x50).
Fig. 3. Nuclear immunohistochemical expression of progesterone
receptors; negative expression in carcinoma cells and negative
expression in myometrial cells (x50).
TABLE 2
EXPRESSION OF STEROID RECEPTORS IN TUMOR CELLS AND IN THE MYOMETRIUM IN CORRELATION WITH PROGNOSTIC
FACTORS IN ENDOMETRIAL CANCER
Prognostic factors ER tumor ER myometrium PGR tumor PGR myometrium
Age/years R –0.17 –0.006 –0.342* –0.205
Tumor size/mm R –0.271* –0.265 –0.209 –0.162
Histological grade R –0.330* –0.054 –0.388* –0.072
Surgical stage R –0.276* –0.036 –0.444* –0.109
ER – estrogen receptors, PGR – progesterone receptors
*p<0.05
PGR, were strongly co-expressed in cancer cells (R=
0.766, p<0.001) as well as in the myometrium (R=0.441,
p=0.001). ER showed a major influence on tumor growth.
Tumors were larger in cases with negative ER (p=0.041)
and, although not statistically significant, lower ER in
the myometrium (p=0.059). A higher histological grade
correlated with the lower expression of ER (p=0.012)
and PGR (p=0.002) in cancer cells, while the status of re-
ceptors in the myometrium had no influence on the
histological grade. The expression of ER and PGR in can-
cer influenced the surgical stage of the disease.
Our results showed that ER and PGR in tumor cells
were markedly lower in high risk than in low risk en-
dometrial cancer, as presented in Table 3. The lower ex-
pression of both receptors in cancer cells also correlated
with the presence of LVSI, yet did not correlate with the
depth of myometrial invasion. We did not find any corre-
lation between ER expression in the myometrium and
disease risk, LVSI or patient outcome but we found that
the expression of PGR in the myometrium correlated
with disease risk (p=0.005).
Discussion
Endometrial cancer is the second most common ma-
lignancy among women aged between 50 and 69 years old
in Croatia. This cancer is usually diagnosed in early stage
and there is good prognosis. The majority of patients
with EC in our study were postmenopausal women, with
a median age of 66 years. Numerous studies have defined
some valuable prognostic factors of this malignancy. The
surgical stage and histopathologic tumor grade are the
most relevant features for subsequent therapeutic man-
agement14,15. The depth of myometrial invasion and posi-
tive LVSI are parameters in terms of recurrence rate and
survival5,16. According to the mentioned parameters, the
endometrioid histological type of carcinoma belongs to a
low-risk malignance while papillary serous and clear cell
carcinomas are high-risk malignancies. Our results are
similar to those reported in previous studies. The higher
risk tumors occurred in older women, with a median age
of 70 years. In addition, the high-risk tumors were of a
larger size and less differentiated, more often with posi-
tive LVSI than low-risk tumors (Table 1). In our study,
low-risk carcinomas corresponded to a lesion in clinical
stage I/II while high-risk carcinomas corresponded to
surgical stage III/IV. Estrogens act as a promoter of
growth and proliferation of the endometrium via estro-
gen receptors, while progesterone acts as an estrogen an-
tagonist in endometrial maturation and inhibition of
proliferation17. The endometrium is very sensitive to sex
hormones, and thus a shift in the balance of estrogens
and progesterone can cause the development of endo-
metrial cancer18. The expression of steroid hormone re-
ceptors is one of the important prognostic factors in
endometrial carcinoma3,4. Data from the literature re-
ported hormone receptors positivity in 35–90% of endo-
metrial carcinomas6–8,18. In our analysis, ER and PGR
were positive in 73.7% and 68.4% of endometrial cancer
nuclei, with a strong co-expression in cancer cells. In
agreement with our results, several studies have re-
ported that a loss of ER expression, correlates with
larger tumor size, poor differentiation, positive LVSI and
a higher clinical stage9. Interestingly, there is disagree-
ment about the impact of ER on myometrial inva-
sion10,11. Our results confirm reports by Jorgen et al that
ER does not influence myometrial invasion10. Jeon et al,
however, found a correlation between ER and myome-
trial invasion10,11. Recent studies have proposed proges-
terone as an ultimate endometrial tumor suppressor18.
They have reported that progesterone via PGR is an in-
hibitor of tumorigenesis. Ito et al suggested that the
invasiveness and metastatic potential of carcinomas can
be influenced by loss of PGR17. In our study, loss of PGR
expression in carcinoma cells correlated with a higher
histological grade and LVSI. We also found a stronger cor-
relation between negative PGR and surgical stage III/IV
and a histological high-risk type of disease than with ER.
In concordance with others we showed that PGR is a
stronger marker of carcinoma aggressiveness13. Interest-
ingly, but opposed to reported results, we did not find a
correlation between PGR and tumor size or myometrial
invasion9–11. Some authors suggested that activation of
the PGR pathway via estrogen can be interrupted13,18.
As reported by Yang et al, the relation between cancer
cells and surrounding tissue may be involved in endome-
trial carcinogenesis18. Experiments have shown constant
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TABLE 3
EXPRESSION OF STEROID RECEPTORS IN TUMOR CELLS AND IN THE MYOMETRIUM IN CORRELATION WITH PROGNOSTIC
FACTORS IN ENDOMETRIAL CANCER
Steroid receptors













ER tumor (%) Mean value 65.8 18.3* 55.3 44.6 65.3 34.4*
ER myometrium (%) Mean value 70.6 70.0 73.1 66.8 74.4 67.0
PGR tumor (%) Mean value 71.9 9.1* 58.6 43.0 67.1 34.2*
pnumPGR myometrium (%) Mean value 85.0 60.6* 77.2 77.1 80.0 74.4*
LVSI – lymphovascular space invasion, ER – estrogen receptors, PGR – progesterone receptors
*p<0.05
communication between epithelial and stromal cells, and
that the critical stages of proliferation are mediated
through the stromal expression of hormones19. Our re-
sults showed that the myometrium is predominantly pos-
itive for ER and PGR and they have a strong co-expres-
sion (R=0.441, p=0.001). In high-risk carcinomas, we
observed lower levels of PGR in the myometrium than
ER (77.7% vs. 92.4%). Since, lack of PGR in carcinoma
correlated with older age, perhaps this lack of PGR in the
myometrium also depends on the age of patients. Lack of
ER in the myometrium had a tendency to correlate with
tumor size. In our study, loss of PGR in the myometrium
influenced the occurrence of high-risk carcinomas. It still
remains to be clarified whether PGR has a protective role
in endometrial carcinogenesis, as reported in some stud-
ies, or whether the loss of PGR is a precondition for carci-
noma development13,20.
In clinical practice, progesterone therapy has been
used in recurrent disease but the response rate has not
been very high (20–30%)2,20. Some results suggest that
an improved response to hormone therapy depends on
the higher expression of PGR13. Although survival analy-
sis was not the subject of this study, we can confirm that
PGR is a strong predictor of EC prognosis. Current strat-
egies for the treatment of EC are still not as effective as
in other types of hormone dependent carcinomas. Thus,
further investigations to improve treatment strategies
are necessary.
Conclusion
Our study confirms the prognostic importance of in-
vestigating the hormonal status in endometrial carcino-
mas, considering the direct correlation between the level
of the sex steroid hormone receptors in relation to tumor
size, tumor differentiation, histological type, LVSI, surgi-
cal stage and the age of patients. Loss of ER and PGR in
carcinoma cells and loss of PGR in the myometrium was
a predictor of a more aggressive type of endometrial can-
cer and consequently a poor prognosis.
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ODNOS IZME\U IZRA@ENOSTI ESTROGENSKIH I PROGESTERONSKIH RECEPTORA U
STANICAMA KARCINOMA I U MIOMETRIJU I PROGNOSTI^KIH ^IMBENIKA KARCINOMA
ENDOMETRIJA
S A @ E T A K
Karcinom endometrija je naj~e{}e maligno oboljenje `enskog spolnog sustava u Republici Hrvatskoj. Cilj je ove stu-
dije utvrditi imunohistokemijsku izra`enost estrogenskih receptora (ER) i progesteronskih receptora (PGR) u karci-
nomskim stanicama i u miometriju te utvrditi odnos s prognosti~kim ~imbenicima karcinoma endometrija. Pozitivni
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ER-i u jezgrama karcinomskih stanica prona|eni su u 42 promatrana slu~aja (73,7%), a pozitivni PGR-i u 39 pro-
matranih slu~ajeva (68,4%). Gubitak ER-a u jezgrama karcinomskih stanica povezan je s veli~inom tumora (p=0,041),
slabom diferencijacijom karcinoma (p=0,012), agresivnijim histolo{kim tipom (p<0,001), invazijom limfovaskularnog
prostora (p=0,002) i vi{im kirur{kim stadijem bolesti (p=0,037). Gubitak PGR-a u jezgrama karcinomskih stanica
povezan je sa starijom dobi pacijentica (p=0,009), slabom diferencijacijom karcinoma (p=0,002), agresivnijim histo-
lo{kim tipom (p<0,001), invazijom limfovaskularnog prostora (p=0,002) i uznapredovalim kirur{kim stadijem bolesti
(p<0,001). Ni`i izra`aj oba receptora nije pokazao povezanost s dubinom invazije miometrija. Gubitak PGR-a u mio-
metriju povezan je s agresivnijim histolo{kim tipom (p=0,005), a gubitak ER-a u miometriju imao je tendenciju kore-
lacije s rastom tumora (p=0,059). Zaklju~ak je studije da je gubitak oba hormonska receptora u karcinomskim stani-
cama i gubitak PGR-a u miometriju naznaka agresivnijeg tipa karcinoma endometrija i lo{e prognoze bolesti.
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